Ilmarinen Mutual Pension Insurance Co Sells 12,200 Shares of Elevance Health, Inc. $ELV

Ilmarinen Mutual Pension Insurance Co decreased its holdings in Elevance Health, Inc. (NYSE:ELV) by 26.2% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 34,400 shares of the company’s stock after selling 12,200 shares during the quarter. Ilmarinen Mutual Pension Insurance Co’s holdings in Elevance Health were worth $12,059,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. Sound View Wealth Advisors Group LLC raised its position in Elevance Health by 3.0% in the 4th quarter. Sound View Wealth Advisors Group LLC now owns 1,011 shares of the company’s stock valued at $354,000 after purchasing an additional 29 shares during the last quarter. Fulton Breakefield Broenniman LLC raised its position in Elevance Health by 3.6% in the 4th quarter. Fulton Breakefield Broenniman LLC now owns 825 shares of the company’s stock valued at $289,000 after purchasing an additional 29 shares during the last quarter. Perigon Wealth Management LLC raised its position in Elevance Health by 2.2% in the 4th quarter. Perigon Wealth Management LLC now owns 1,371 shares of the company’s stock valued at $481,000 after purchasing an additional 29 shares during the last quarter. Savvy Advisors Inc. raised its position in Elevance Health by 3.2% in the 4th quarter. Savvy Advisors Inc. now owns 979 shares of the company’s stock valued at $343,000 after purchasing an additional 30 shares during the last quarter. Finally, CoreCap Advisors LLC raised its position in Elevance Health by 6.1% in the 4th quarter. CoreCap Advisors LLC now owns 557 shares of the company’s stock valued at $195,000 after purchasing an additional 32 shares during the last quarter. Institutional investors own 89.24% of the company’s stock.

Elevance Health Stock Up 0.3%

NYSE:ELV opened at $392.47 on Friday. Elevance Health, Inc. has a 1 year low of $273.71 and a 1 year high of $408.00. The company has a current ratio of 1.48, a quick ratio of 1.48 and a debt-to-equity ratio of 0.70. The stock has a market cap of $85.23 billion, a price-to-earnings ratio of 16.69, a PEG ratio of 2.21 and a beta of 0.66. The stock has a 50-day moving average price of $341.76 and a two-hundred day moving average price of $338.51.

Elevance Health (NYSE:ELV) last posted its earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.74 by $1.84. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The firm had revenue of $49.49 billion during the quarter, compared to analysts’ expectations of $48.21 billion. During the same period in the previous year, the firm earned $11.97 earnings per share. The company’s revenue was up 1.5% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 19.850- EPS. As a group, equities analysts expect that Elevance Health, Inc. will post 26.93 earnings per share for the current year.

Elevance Health Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 25th. Shareholders of record on Wednesday, June 10th will be paid a $1.72 dividend. This represents a $6.88 dividend on an annualized basis and a yield of 1.8%. The ex-dividend date of this dividend is Wednesday, June 10th. Elevance Health’s payout ratio is presently 29.26%.

Analyst Ratings Changes

A number of research firms have recently weighed in on ELV. Wells Fargo & Company dropped their target price on Elevance Health from $424.00 to $391.00 and set an “overweight” rating for the company in a research report on Friday, January 30th. Royal Bank Of Canada downgraded Elevance Health from an “outperform” rating to a “sector perform” rating and set a $358.00 target price for the company. in a research report on Tuesday, February 3rd. Truist Financial dropped their target price on Elevance Health from $390.00 to $375.00 and set a “buy” rating for the company in a research report on Monday, April 13th. Evercore restated a “hold” rating on shares of Elevance Health in a research report on Tuesday, May 19th. Finally, Deutsche Bank Aktiengesellschaft upgraded Elevance Health from a “hold” rating to a “buy” rating and boosted their target price for the stock from $363.00 to $498.00 in a research report on Wednesday, May 20th. Fourteen research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $403.11.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.